|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...96979899100101102103104105106...156157» |
- Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion date: A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - May 11, 2014
P3, N=15, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2014 --> Nov 2014
- Clinical: Continuous Glucose Monitoring and Metabolic Control in Children With Type 1 Diabetes (clinicaltrials.gov) - May 11, 2014
P=N/A, N=40, Completed, Sponsor: University of Toronto
- || New P2/3 trial: Home and School Visits Intervention for Children With DM TYPE 1 (clinicaltrials.gov) - May 11, 2014
P2/3, N=92, Completed, Sponsor: Ben-Gurion University of the Negev
- || Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment closed, Monotherapy: An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - May 11, 2014
P=N/A, N=107, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Sep 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change: A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab) (clinicaltrials.gov) - May 11, 2014
P=N/A, N=20, Not yet recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting N=50 --> 20
- Trial completion date, IO biomarker: Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples (clinicaltrials.gov) - May 10, 2014
P1, N=400, Recruiting, Sponsor: Carmel Medical Center
N=50 --> 20 Trial completion date: Oct 2015 --> Dec 2015
- || dalfampridine / Generic mfg.
Trial primary completion date: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - May 8, 2014
P4, N=125, Completed, Sponsor: University of Southern Denmark
Trial completion date: Oct 2015 --> Dec 2015 Trial primary completion date: Dec 2012 --> May 2014
- || dalfampridine / Generic mfg.
Trial completion date: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - May 8, 2014
P4, N=125, Completed, Sponsor: University of Southern Denmark
Trial primary completion date: Dec 2012 --> May 2014 Trial completion date: Dec 2012 --> May 2014
- |||| dalfampridine / Generic mfg.
Trial completion: FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra (clinicaltrials.gov) - May 8, 2014
P4, N=125, Completed, Sponsor: University of Southern Denmark
Trial completion date: Dec 2012 --> May 2014 Active, not recruiting --> Completed
- Trial primary completion date: Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes. (clinicaltrials.gov) - May 8, 2014
P=N/A, N=40, Recruiting, Sponsor: Park Nicollet Institute
Active, not recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2015
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial primary completion date: BRiTE: Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab (clinicaltrials.gov) - May 8, 2014
P2, N=0, Withdrawn, Sponsor: Emory University
Trial primary completion date: Dec 2013 --> Dec 2015 Trial primary completion date: Sep 2013 --> Nov 2009
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial withdrawal: BRiTE: Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab (clinicaltrials.gov) - May 8, 2014
P2, N=0, Withdrawn, Sponsor: Emory University
Trial primary completion date: Sep 2013 --> Nov 2009 Terminated --> Withdrawn
- Trial completion date: Develop and Validate a Self-Administered Instrument That Will Screen for Eating Disorder Symptoms in Persons Aged 12 and Older With Type 1 Diabetes. (clinicaltrials.gov) - May 8, 2014
P=N/A, N=40, Recruiting, Sponsor: Park Nicollet Institute
Terminated --> Withdrawn Trial completion date: Dec 2013 --> Dec 2015
- Raptiva (efalizumab) / Roche, EMD Serono, Xoma
Trial completion date: BRiTE: Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab (clinicaltrials.gov) - May 8, 2014
P2, N=0, Withdrawn, Sponsor: Emory University
Trial completion date: Dec 2013 --> Dec 2015 Trial completion date: Sep 2013 --> Nov 2009
- || MK-8808 (rituximab biosimilar) / Merck (MSD)
Clinical: A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) (clinicaltrials.gov) - May 8, 2014
P1, N=100, Completed, Sponsor: Merck Sharp & Dohme Corp.
Trial completion date: Sep 2013 --> Nov 2009 N=180 --> 100
- ||| MK-8808 (rituximab biosimilar) / Merck (MSD)
Clinical: A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) (clinicaltrials.gov) - May 8, 2014
P1, N=100, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=180 --> 100 Active, not recruiting --> Completed
- gimsilumab (KIN-1901) / Roivant, Eisai
Trial primary completion date: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - May 7, 2014
P1, N=19, Active, not recruiting, Sponsor: Morphotek
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Jul 2014
- gimsilumab (KIN-1901) / Roivant, Eisai
Trial completion date: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - May 7, 2014
P1, N=19, Active, not recruiting, Sponsor: Morphotek
Trial primary completion date: May 2014 --> Jul 2014 Trial completion date: May 2014 --> Jan 2015
- gimsilumab (KIN-1901) / Roivant, Eisai
Enrollment closed: MORAB022-001: Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects (clinicaltrials.gov) - May 7, 2014
P1, N=19, Active, not recruiting, Sponsor: Morphotek
Trial completion date: May 2014 --> Jan 2015 Recruiting --> Active, not recruiting
- |||| Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. (clinicaltrials.gov) - May 7, 2014
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Dec 2015 --> Sep 2015
- ||| Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion date: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. (clinicaltrials.gov) - May 7, 2014
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Sep 2015 Trial completion date: Jan 2016 --> Sep 2015
- |||||| Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
Enrollment open: A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. (clinicaltrials.gov) - May 7, 2014
P3, N=100, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jan 2016 --> Sep 2015 Not yet recruiting --> Recruiting
- Trial primary completion date: FingoHRV: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P=N/A, N=27, Completed, Sponsor: Kuopio University Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Mar 2014
- || Orencia (abatacept) / BMS
Trial initiation date: ACTION: Long Term Experience With Abatacept in Routine Clinical Practice (clinicaltrials.gov) - May 6, 2014
P=N/A, N=1255, Recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Dec 2016 --> Mar 2014 Initiation date: May 2008 --> Mar 2008
- Trial completion date: FingoHRV: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P=N/A, N=27, Completed, Sponsor: Kuopio University Hospital
Initiation date: May 2008 --> Mar 2008 Trial completion date: Dec 2016 --> Mar 2014
- cyclosporin A microemulsion / Generic mfg.
Trial primary completion date: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial completion date: Dec 2016 --> Mar 2014 Trial primary completion date: Jan 2014 --> Oct 2014
- cyclosporin A microemulsion / Generic mfg.
Trial completion date: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial primary completion date: Jan 2014 --> Oct 2014 Trial completion date: Mar 2014 --> Oct 2014
- cyclosporin A microemulsion / Generic mfg.
Enrollment closed: CYPRESS: Low Dose Cyclosporin A in Primary Sjögren Syndrome (clinicaltrials.gov) - May 6, 2014
P2, N=30, Active, not recruiting, Sponsor: Charite University, Berlin, Germany
Trial completion date: Mar 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- Trial completion: FingoHRV: Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P=N/A, N=27, Completed, Sponsor: Kuopio University Hospital
Recruiting --> Active, not recruiting Recruiting --> Completed
- toreforant (JNJ-38518168) / J&J
Trial primary completion date, Biopsy: A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy (clinicaltrials.gov) - May 6, 2014
P2, N=25, Recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Trial primary completion date: Apr 2014 --> Oct 2015
- Trial primary completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - May 6, 2014
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Apr 2014 --> Oct 2015 Trial primary completion date: Oct 2013 --> Feb 2015
- Trial completion date: PLASMASEP: Plasma Exchanges in Multiple Sclerosis (MS) Relapses (clinicaltrials.gov) - May 6, 2014
P3, N=80, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Oct 2013 --> Feb 2015 Trial completion date: Sep 2014 --> Jul 2015
- || Orencia (abatacept) / BMS
Enrollment change: ACTION: Long Term Experience With Abatacept in Routine Clinical Practice (clinicaltrials.gov) - May 6, 2014
P=N/A, N=1255, Recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Sep 2014 --> Jul 2015 N=2825 --> 1255
- Enrollment change: Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P1/2, N=39, Completed, Sponsor: Oregon Health and Science University
N=2825 --> 1255 N=50 --> 39
- || Orencia (abatacept) / BMS
Enrollment change: Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe (clinicaltrials.gov) - May 6, 2014
P1, N=216, Recruiting, Sponsor: Bristol-Myers Squibb
N=50 --> 39 N=180 --> 216
- | New P1/2 trial: Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis (clinicaltrials.gov) - May 6, 2014
P1/2, N=53, Not yet recruiting, Sponsor: Oregon Health and Science University
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
Enrollment open: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - May 5, 2014
P1, N=32, Recruiting, Sponsor: Novo Nordisk A/S
N=180 --> 216 Not yet recruiting --> Recruiting
- |||| Betaseron (IFN-β-1b) / Bayer
Trial completion: BENEFIT 11: Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis (clinicaltrials.gov) - May 4, 2014
P4, N=365, Completed, Sponsor: Bayer
Not yet recruiting --> Recruiting Recruiting --> Completed
- Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: The Effect of Natalizumab (Tysabri) on Sexual Dysfunction in Multiple Sclerosis (clinicaltrials.gov) - May 4, 2014
P=N/A, N=30, Recruiting, Sponsor: University of South Florida
Recruiting --> Completed Trial primary completion date: Dec 2013 --> Oct 2014
- ZB-168 / Zura Bio
Trial primary completion date: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2014
P1, N=40, Recruiting, Sponsor: Pfizer
Trial primary completion date: Dec 2013 --> Oct 2014 Trial primary completion date: May 2015 --> Jun 2015
- ZB-168 / Zura Bio
Trial completion date: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2014
P1, N=40, Recruiting, Sponsor: Pfizer
Trial primary completion date: May 2015 --> Jun 2015 Trial completion date: May 2015 --> Jun 2015
- Clinical: The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes (clinicaltrials.gov) - May 4, 2014
P=N/A, N=150, Not yet recruiting, Sponsor: Rabin Medical Center
- Clinical: Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis (clinicaltrials.gov) - May 4, 2014
P=N/A, N=53, Completed, Sponsor: Fondazione Don Carlo Gnocchi Onlus
- Clinical: Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus (clinicaltrials.gov) - May 4, 2014
P=N/A, N=50, Completed, Sponsor: Mount Sinai School of Medicine
- | Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial primary completion date: An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - May 4, 2014
P3, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: May 2015 --> Jun 2015 Trial primary completion date: Dec 2014 --> May 2015
- Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial completion date: An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis (clinicaltrials.gov) - May 4, 2014
P3, N=50, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2014 --> May 2015 Trial completion date: Dec 2014 --> May 2015
- Fiasp (fast-acting insulin aspart) / Novo Nordisk
New P1 trial: A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2014
P1, N=32, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ZB-168 / Zura Bio
Enrollment open: A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes (clinicaltrials.gov) - May 4, 2014
P1, N=40, Recruiting, Sponsor: Pfizer
Trial completion date: Dec 2014 --> May 2015 Not yet recruiting --> Recruiting
- Trial primary completion date, HEOR: The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes (clinicaltrials.gov) - May 3, 2014
P=N/A, N=30, Completed, Sponsor: Rabin Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2013 --> Aug 2013
- Trial completion date, HEOR: The Effect of the Use of Computer Game- "My Diabetic Friend" in Children With Type 1 Diabetes (clinicaltrials.gov) - May 3, 2014
P=N/A, N=30, Completed, Sponsor: Rabin Medical Center
Trial primary completion date: Jun 2013 --> Aug 2013 Trial completion date: Dec 2013 --> Aug 2013